Protective effect of Acticoa powder, a cocoa polyphenolic extract, on prostate carcinogenesis in Wistar-Unilever rats.
The effects of Acticoa powder on prostate carcinogenesis were investigated using the N-methylnitrosourea and testosterone propionate prostate tumor model. Sixty male Wistar-Unilever rats were randomly divided in four groups of 15 rats: one control group not induced but treated with vehicle (not induced+vehicle) and three chemo-induced groups. Two weeks before prostate tumor induction and then throughout the experiment, chemo-induced rats were orally treated with Acticoa powder at 24 (chemo-induced+Acticoa powder24) or 48 (chemo-induced+Acticoa powder48) mg/kg or with vehicle (chemo-induced+vehicle), daily from Monday to Friday. Survival, body weight, food and water consumption were recorded throughout the experiment. Six rats per group were randomly killed 9 months after the prostate tumor induction for histopathological analysis of prostates. A reduction in the incidence of prostate tumors was observed for the chemo-induced+Acticoa powder48-treated group in comparison with the chemo-induced+vehicle-treated group and no tumors were observed in the chemo-induced+Acticoa powder24-treated group as in the not induced+vehicle-treated group after 9 months. The nine remaining rats per group were maintained in a long-term survival study. The life span of the chemo-induced+Acticoa powder24-treated group was significantly increased in comparison with the chemo-induced+Acticoa powder48 and the chemo-induced+vehicle-treated groups, close to the one of the not induced+vehicle-treated group. A significant reduction in the incidence of prostate tumors was also observed for the chemo-induced+Acticoa powder24 and chemo-induced+Acticoa powder48-treated groups in comparison with the chemo-induced+vehicle-treated group. In conclusion, Acticoa powder at 24 mg/kg protected rats from prostate carcinogenesis when chronically given before the initiation and promotion phases of induction.
Bisson
Jean-François
JF
ETAP-Ethologie Appliquée, Centre de Recherche en Pharmacologie, Cancérologie et Nutrition, Vandoeuvre-lès-Nancy, France. jfbisson@etap-lab.com
Guardia-Llorens
Maria-Alba
MA
Hidalgo
Sophie
S
Rozan
Pascale
P
Messaoudi
Michaël
M
D000284:Administration, Oral; D000818:Animals; D016588:Anticarcinogenic Agents / Q000627:therapeutic use*; D001835:Body Weight / Q000187:drug effects; D002099:Cacao / Q000737:chemistry*; D002273:Carcinogens / Q000633:toxicity; D002471:Cell Transformation, Neoplastic; D003043:Cocarcinogenesis; D004195:Disease Models, Animal; D005419:Flavonoids / Q000008:administration & dosage*; D008297:Male; D008770:Methylnitrosourea / Q000633:toxicity; D010636:Phenols / Q000008:administration & dosage*; D010936:Plant Extracts / Q000627:therapeutic use*; D059808:Polyphenols; D011471:Prostatic Neoplasms / Q000139:chemically induced / Q000473:pathology / Q000517:prevention & control*; D051381:Rats; D017208:Rats, Wistar; D043343:Testosterone Propionate / Q000633:toxicity
D016588:Anticarcinogenic Agents; D002273:Carcinogens; D005419:Flavonoids; D010636:Phenols; D010936:Plant Extracts; D059808:Polyphenols; D008770:Methylnitrosourea; D043343:Testosterone Propionate